GSK Sues Mylan, Impax Over Generic Prostate Drugs

Law360, New York (September 9, 2011, 9:47 PM EDT) -- GlaxoSmithKline PLC filed a lawsuit Friday accusing Mylan Inc. and Impax Laboratories Inc. of infringing three patents that cover its enlarged prostate treatments, Avodart and Jalyn.

Mylan and Impax, both Pennsylvania-based generic-drug makers, submitted applications to the U.S. Food and Drug Administration for approval to manufacture generic versions of the two products.

GSK claims the companies infringed the patents for Avodart, which was approved by the FDA for the treatment of symptomatic benign prostatic hyperplasia in 2001, and Jalyn, another treatment for the condition that was...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.